Entry - #618963 - IMMUNODEFICIENCY 69; IMD69 - OMIM - (OMIM.ORG)
# 618963

IMMUNODEFICIENCY 69; IMD69


Alternative titles; symbols

IMMUNODEFICIENCY 69, MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE
IFNG DEFICIENCY, AUTOSOMAL RECESSIVE


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12q15 ?Immunodeficiency 69, mycobacteriosis 618963 AR 3 IFNG 147570
Clinical Synopsis
 
Phenotypic Series
 

INHERITANCE - Autosomal recessive [SNOMEDCT: 258211005] [UMLS: C0441748 HPO: HP:0000007] [HPO: HP:0000007] ABDOMEN Liver - Hepatomegaly [SNOMEDCT: 80515008] [ICD10CM: R16. 0] [ICD9CM: 789. 1] [UMLS: C0019209 HPO: HP:0002240] [HPO: HP:0002240] Spleen - Splenomegaly [SNOMEDCT: 16294009] [ICD10CM: R16. 1] [ICD9CM: 789. 2] [UMLS: C0038002 HPO: HP:0001744] [HPO: HP:0001744] SKIN, NAILS, & HAIR Skin - Maculopapular rash (1 patient) [SNOMEDCT: 247471006, 47725002] [UMLS: C0423791 HPO: HP:0040186] METABOLIC FEATURES - Fever [SNOMEDCT: 50177009, 386661006] [ICD10CM: R50. 9] [ICD9CM: 780. 60] [UMLS: C0424755, C0015967 HPO: HP:0001945] [HPO: HP:0001945] HEMATOLOGY - Anemia [SNOMEDCT: 271737000] [ICD10CM: D64. 9] [ICD9CM: 285. 9] [UMLS: C1000483, C0002871 HPO: HP:0001903] [HPO: HP:0001903] - Thrombocytosis [SNOMEDCT: 6631009] [ICD10CM: D75. 83, D75. 839] [UMLS: C0836924 HPO: HP:0001894] [HPO: HP:0001894] IMMUNOLOGY - Susceptibility to disseminated mycobacterial infection [UMLS: C4315619] - Leukocytosis during infection [UMLS: C5436499] - T and NK cells show impaired production of gamma-interferon when stimulated [UMLS: C5436500] LABORATORY ABNORMALITIES - Elevated liver enzymes [UMLS: C0235996 HPO: HP:0002910] [HPO: HP:0002910] MISCELLANEOUS - Onset in infancy [UMLS: C1848924 HPO: HP:0003593] [HPO: HP:0003593] - Onset triggered by BCG vaccination - Patients do not develop severe infections to other viral or bacterial organisms - One consanguineous Lebanese family has been reported (last curated July 2020) MOLECULAR BASIS - Caused by mutation in the interferon gamma gene (IFNG, 147570. 0005) ▲ Close Immunodeficiency (select examples) - PS300755 - 144 Entries Location Phenotype Inheritance Phenotypemapping key PhenotypeMIM number Gene/Locus Gene/LocusMIM number 1p36. 33 Immunodeficiency 38 AR 3 616126 ISG15 147571 1p36. 33 . Immunodeficiency 16 AR 3 615593 TNFRSF4 600315 1p36. 23 Immunodeficiency 109 with lymphoproliferation AR 3 620282 TNFRSF9 602250 1p36. 22 Immunodeficiency 14B, autosomal recessive AR 3 619281 PIK3CD 602839 1p36. 22 Immunodeficiency 14A, autosomal dominant AD 3 615513 PIK3CD 602839 1p35. 2 Immunodeficiency 22 AR 3 615758 LCK 153390 1p34. 2 Immunodeficiency 24 AR 3 615897 CTPS1 123860 1p22. 3 . Immunodeficiency 37 AR 3 616098 BCL10 603517 1q21. 3 Immunodeficiency 42 AR 3 616622 RORC 602943 1q23. 3 Immunodeficiency 20 AR 3 615707 FCGR3A 146740 1q24. 2 . Immunodeficiency 25 AR 3 610163 CD247 186780 1q25. 3 Immunodeficiency 113 with autoimmunity and autoinflammation AR 3 620565 ARPC5 604227 1q25. 3 Immunodeficiency 70 AD 3 618969 IVNS1ABP 609209 1q31. 3-q32. 1 Immunodeficiency 105, severe combined AR 3 619924 PTPRC 151460 2p16. 1 Immunodeficiency 92 AR 3 619652 REL 164910 2p11. 2 Immunodeficiency 116 AR 3 608957 CD8A 186910 2q11. 2 Immunodeficiency 48 AR 3 269840 ZAP70 176947 2q24. 2 Immunodeficiency 95 AR 3 619773 IFIH1 606951 2q32 V体育官网. 2 Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive AR 3 613796 STAT1 600555 2q32. 2 Immunodeficiency 31C, chronic mucocutaneous candidiasis, autosomal dominant AD 3 614162 STAT1 600555 2q32. 2 Immunodeficiency 31A, mycobacteriosis, autosomal dominant AD 3 614892 STAT1 600555 2q33. 2 . Immunodeficiency 123 with HPV-related verrucosis AR 3 620901 CD28 186760 2q35 Immunodeficiency 124, severe combined AR 3 611291 NHEJ1 611290 3p22. 2 Immunodeficiency 68 AR 3 612260 MYD88 602170 3q21. 3 Immunodeficiency 21 AD 3 614172 GATA2 137295 3q21. 3 . Immunodeficiency 128 AR 3 620983 COPG1 615525 3q29 Immunodeficiency 46 AR 3 616740 TFRC 190010 4p14 Immunodeficiency 129 AR 3 618307 RHOH 602037 4q24 Immunodeficiency 75 AR 3 619126 TET2 612839 4q35. 1 {Immunodeficiency 83, susceptibility to viral infections} AD, AR 3 613002 TLR3 603029 5p15. 2 {Immunodeficiency 107, susceptibility to invasive staphylococcus aureus infection} AD 3 619986 OTULIN 615712 5p13. 2 Immunodeficiency 104, severe combined AR 3 608971 IL7R 146661 5q11. 2 . Immunodeficiency 94 with autoinflammation and dysmorphic facies AD 3 619750 IL6ST 600694 5q13. 1 Immunodeficiency 36 AD 3 616005 PIK3R1 171833 5q31. 1 Immunodeficiency 93 and hypertrophic cardiomyopathy AR 3 619705 FNIP1 610594 5q31. 1 Immunodeficiency 117, mycobacteriosis, autosomal recessive AR 3 620668 IRF1 147575 5q33. 3 Immunodeficiency 29, mycobacteriosis AR 3 614890 IL12B 161561 5q35. 1 Immunodeficiency 40 AR 3 616433 DOCK2 603122 5q35. 1 Immunodeficiency 81 AR 3 619374 LCP2 601603 6p25. 3 Immunodeficiency 131 AD, AR 3 621097 IRF4 601900 6p25. 2 Immunodeficiency 57 with autoinflammation AR 3 618108 RIPK1 603453 6p21. 33 . Immunodeficiency 127 AR 3 620977 TNF 191160 6p21. 31 Immunodeficiency 133 with ectodermal dysplasia with or without peripheral neuropathy AD 3 621254 ITPR3 147267 6p21. 31 Immunodeficiency 87 and autoimmunity AR 3 619573 DEF6 610094 6p21. 1 Immunodeficiency 126 AR 3 620931 PTCRA 606817 6q14. 1 Immunodeficiency 23 AR 3 615816 PGM3 172100 6q15 Immunodeficiency 60 and autoimmunity AD 3 618394 BACH2 605394 6q23. 3 Immunodeficiency 27B, mycobacteriosis, AD AD 3 615978 IFNGR1 107470 6q23. 3 Immunodeficiency 27A, mycobacteriosis, AR AR 3 209950 IFNGR1 107470 7p22. 2 Immunodeficiency 11A AR 3 615206 CARD11 607210 7p22. 2 Immunodeficiency 11B with atopic dermatitis AD 3 617638 CARD11 607210 7q22. 1 Immunodeficiency 71 with inflammatory disease and congenital thrombocytopenia AR 3 617718 ARPC1B 604223 7q22. 3 Immunodeficiency 97 with autoinflammation AR 3 619802 PIK3CG 601232 8p11. 21 Immunodeficiency 15B AR 3 615592 IKBKB 603258 8p11. 21 Immunodeficiency 15A AD 3 618204 IKBKB 603258 8q11. 21 Immunodeficiency 26, with or without neurologic abnormalities AR 3 615966 PRKDC 600899 8q11. 21 Immunodeficiency 54 AR 3 609981 MCM4 602638 8q21. 13 Immunodeficiency 130 with HPV-related verrucosis AR 3 618309 IL7 146660 9q22. 2 Immunodeficiency 82 with systemic inflammation AD 3 619381 SYK 600085 9q34. 3 Immunodeficiency 103, susceptibility to fungal infection AR 3 212050 CARD9 607212 10p15. 1 Immunodeficiency 41 with lymphoproliferation and autoimmunity AR 3 606367 IL2RA 147730 10p13 Immunodeficiency 80 with or without cardiomyopathy AR 3 619313 MCM10 609357 11p15. 5 Immunodeficiency 39 AR 3 616345 IRF7 605047 11p15. 4 Immunodeficiency 10 AR 3 612783 STIM1 605921 11q12. 1 Immunodeficiency 77 AD 3 619223 MPEG1 610390 11q13. 3 Immunodeficiency 90 with encephalopathy, functional hyposplenia, and hepatic dysfunction AR 3 613759 FADD 602457 11q13. 4 Immunodeficiency 122 AR 3 620869 POLD3 611415 11q23. 3 Immunodeficiency 18, SCID variant AR 3 615615 CD3E 186830 11q23. 3 Immunodeficiency 18 AR 3 615615 CD3E 186830 11q23. 3 Immunodeficiency 19, severe combined AR 3 615617 CD3D 186790 11q23. 3 Immunodeficiency 17, CD3 gamma deficient AR 3 615607 CD3G 186740 11q23. 3 . Immunodeficiency 59 and hypoglycemia AR 3 233600 HYOU1 601746 12p13. 31 Immunodeficiency 79 AR 3 619238 CD4 186940 12q12 Immunodeficiency 67 AR 3 607676 IRAK4 606883 12q13. 13-q13. 2 Immunodeficiency 72 with autoinflammation AR 3 618982 NCKAP1L 141180 12q13. 3 Immunodeficiency 44 AR 3 616636 STAT2 600556 12q15 . Immunodeficiency 69, mycobacteriosis AR 3 618963 IFNG 147570 12q24. 13 Immunodeficiency 100 with pulmonary alveolar proteinosis and hypogammaglobulinemia AD 3 618042 OAS1 164350 12q24. 31 Immunodeficiency 9 AR 3 612782 ORAI1 610277 13q33. 1 Immunodeficiency 78 with autoimmunity and developmental delay AR 3 619220 TPP2 190470 14q11. 2 Immunodeficiency 7, TCR-alpha/beta deficient AR 3 615387 TRAC 186880 14q11. 2 . Immunodeficiency 108 with autoinflammation AR 3 260570 CEBPE 600749 14q12 Immunodeficiency 115 with autoinflammation AR 3 620632 RNF31 612487 14q12 Immunodeficiency 65, susceptibility to viral infections AR 3 618648 IRF9 147574 14q32. 2 Immunodeficiency 49, severe combined AD 3 617237 BCL11B 606558 14q32. 32 Immunodeficiency 132A AD 3 614849 TRAF3 601896 14q32. 32 Immunodeficiency 132B AD 3 621096 TRAF3 601896 15q14 Immunodeficiency 64 AR 3 618534 RASGRP1 603962 15q21. 1 Immunodeficiency 43 AR 3 241600 B2M 109700 15q21. 2 Immunodeficiency 86, mycobacteriosis AR 3 619549 SPPL2A 608238 16p12. 1 Immunodeficiency 56 AR 3 615207 IL21R 605383 16p11. 2 Immunodeficiency 52 AR 3 617514 LAT 602354 16p11. 2 Immunodeficiency 8 AR 3 615401 CORO1A 605000 16q22. 1 Immunodeficiency 58 AR 3 618131 CARMIL2 610859 16q22. 1 Immunodeficiency 121 with autoinflammation AD 3 620807 PSMB10 176847 16q24. 1 Immunodeficiency 32A, mycobacteriosis, autosomal dominant AD 3 614893 IRF8 601565 16q24. 1 Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive AR 3 226990 IRF8 601565 17q11. 2 . Immunodeficiency 13 AD 3 615518 UNC119 604011 17q12-q21. 1 . Immunodeficiency 84 AD 3 619437 IKZF3 606221 17q21. 31 Immunodeficiency 112 AR 3 620449 MAP3K14 604655 17q21. 32 . Immunodeficiency 88 AR 3 619630 TBX21 604895 18q21. 32 Immunodeficiency 12 AR 3 615468 MALT1 604860 19p13. 3 Hatipoglu immunodeficiency syndrome AR 3 620331 DPP9 608258 19p13. 2 Immunodeficiency 35 AR 3 611521 TYK2 176941 19p13. 11 Immunodeficiency 76 AR 3 619164 FCHO1 613437 19p13. 11 Immunodeficiency 30 AR 3 614891 IL12RB1 601604 19q13. 2 . Immunodeficiency 62 AR 3 618459 ARHGEF1 601855 19q13. 32 Immunodeficiency 53 AR 3 617585 RELB 604758 19q13. 33 Immunodeficiency 96 AR 3 619774 LIG1 126391 19q13. 33 . Immunodeficiency 125 AR 3 620926 FLT3LG 600007 19q13. 33 Immunodeficiency 120 AR 3 620836 POLD1 174761 20p11. 23 . Immunodeficiency 101 (varicella zoster virus-specific) AD 3 619872 POLR3F 617455 20p11. 21 Immunodeficiency 55 AR 3 617827 GINS1 610608 20q11. 23 . Immunodeficiency 99 with hypogammaglobulinemia and autoimmune cytopenias AR 3 619846 CTNNBL1 611537 20q13. 12 T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations AR 3 614868 STK4 604965 20q13. 13 Immunodeficiency 91 and hyperinflammation AR 3 619644 ZNFX1 618931 21q22. 11 Immunodeficiency 45 AR 3 616669 IFNAR2 602376 21q22. 11 Immunodeficiency 106, susceptibility to viral infections AR 3 619935 IFNAR1 107450 21q22. 11 Immunodeficiency 28, mycobacteriosis AR 3 614889 IFNGR2 147569 21q22. 3 . Immunodeficiency 119 AR 3 620825 ICOSLG 605717 21q22. 3 Immunodeficiency 114, folate-responsive AR 3 620603 SLC19A1 600424 22q11. 1 Immunodeficiency 51 AR 3 613953 IL17RA 605461 22q12. 3 . Immunodeficiency 85 and autoimmunity AD 3 619510 TOM1 604700 22q12. 3 Immunodeficiency 63 with lymphoproliferation and autoimmunity AR 3 618495 IL2RB 146710 22q13. 1 . Immunodeficiency 73C with defective neutrophil chemotaxis and hypogammaglobulinemia AR 3 618987 RAC2 602049 22q13. 1 Immunodeficiency 73B with defective neutrophil chemotaxis and lymphopenia AD 3 618986 RAC2 602049 22q13. 1 Immunodeficiency 73A with defective neutrophil chemotaxix and leukocytosis AD 3 608203 RAC2 602049 22q13. 1 . Immunodeficiency 89 and autoimmunity AR 3 619632 CARD10 607209 22q13. 1-q13. 2 . Immunodeficiency 66 AR 3 618847 MKL1 606078 Xp22. 2 Immunodeficiency 74, COVID19-related, X-linked XLR 3 301051 TLR7 300365 Xp22. 2 Immunodeficiency 98 with autoinflammation, X-linked SMo, XL 3 301078 TLR8 300366 Xp22. 12 . Immunodeficiency 61 XLR 3 300310 SH3KBP1 300374 Xp21. 1-p11. 4 Immunodeficiency 34, mycobacteriosis, X-linked XLR 3 300645 CYBB 300481 Xp11. 23 Wiskott-Aldrich syndrome XLR 3 301000 WAS 300392 Xq12 Immunodeficiency 50 XLR 3 300988 MSN 309845 Xq13. 1 Severe combined immunodeficiency, X-linked XLR 3 300400 IL2RG 308380 Xq13. 1 Combined immunodeficiency, X-linked, moderate XLR 3 312863 IL2RG 308380 Xq22. 1 Agammaglobulinemia, X-linked 1 XLR 3 300755 BTK 300300 Xq24 Immunodeficiency 118, mycobacteriosis XLR 3 301115 MCTS1 300587 Xq25 Lymphoproliferative syndrome, X-linked, 1 XLR 3 308240 SH2D1A 300490 Xq26. 1 Immunodeficiency 102 XLR 3 301082 SASH3 300441 Xq26. 3 Immunodeficiency, X-linked, with hyper-IgM XLR 3 308230 TNFSF5 300386 Xq28 Immunodeficiency 47 XLR 3 300972 ATP6AP1 300197 Xq28 Immunodeficiency 33 XLR 3 300636 IKBKG 300248 ▲ Close ▼ TEXT A number sign (#) is used with this entry because of evidence that immunodeficiency-69 (IMD69) is caused by homozygous mutation in the IFNG gene (147570) on chromosome 12q15. One such family has been reported.


Description

Immunodeficiency-69 (IMD69) is an autosomal recessive disorder characterized by increased susceptibility to disseminated mycobacterial infection, including after BCG (bacille Calmette-Guerin) vaccination. Affected individuals develop fever, hepatosplenomegaly, leukocytosis, and thrombocytosis during the acute infection. There appears to be normal immunologic function against other pathogens, including viruses and bacteria. Immunologic work-up shows normal parameters, but patient T and NK cells fail to produce gamma-interferon (IFNG) when stimulated in vitro (summary by Kerner et al VSports手机版. , 2020). .

IMD69 is a form of mendelian susceptibility to mycobacterial disease (MSMD) (see, e. g. , IMD27A; 209950) V体育安卓版.


Clinical Features

Kerner et al. (2020) reported 2 children from a large consanguineous kindred of Lebanese descent who developed disseminated mycobacterial disease following BCG vaccination in early infancy. Clinical features included prolonged fever and hepatosplenomegaly; 1 patient developed a maculopapular rash. Laboratory studies showed leukocytosis, anemia, thrombocytosis, and elevated liver enzymes. One patient was treated with recombinant gamma-interferon. However, she later developed features of hemophagocytic lymphohistiocytosis (HLH) with fever, splenomegaly, pancytopenia, high ferritin (see 134790), and increased triglycerides. Mutations in known HLH genes were excluded, and no infectious agent was identified V体育ios版. She underwent hematopoietic bone marrow transplant at 3 years of age, but died soon thereafter. The second patient, who was a first cousin of the first patient, had a similar early disease course after BCG vaccination and was successfully treated with antimycobacterial medications. Other immunologic parameters in the patients were normal, and antibody testing indicated that both patients had been exposed to bacteria and viruses, including respiratory syncytial virus (RSV), herpes, and opportunistic bacteria, but neither developed significant disease with these organisms. .


Inheritance

The transmission pattern of IMD69 in the family reported by Kerner et al. (2020) was consistent with autosomal recessive inheritance VSports最新版本. .


Molecular Genetics

In 2 patients from a large consanguineous kindred of Lebanese descent with IMD69, Kerner et al. (2020) identified a homozygous frameshift mutation in the IFNG gene (147570. 0005). The mutation, which was found by a combination of homozygosity mapping and whole-exome sequencing and confirmed by Sanger sequencing, segregated with the disorder in the family. Patient cells showed decreased levels of IFNG mRNA compared to controls, suggesting some mRNA decay of the mutant transcript V体育平台登录. The predicted truncated protein, if expressed, would lack the C-terminal domain and likely be nonfunctional. In vitro functional expression studies of patient T cells and cells transfected with the mutation showed impaired IFNG production when stimulated and impaired induction of HLA-DR compared to controls, consistent with a complete loss of IFNG function. These cellular defects could be partially rescued by expression of wildtype IFNG. .


REFERENCES

Kerner, G. , Rosain, J. , Guerin, A. , Al-Khabaz, A. , Oleaga-Quintas, C. , Rapaport, F. , Massaad, M. J. , Ding, J. -Y. , Khan, T. , Ali, F. A. , Rahman, M. , Deswarte, C. , and 18 others. Inherited human IFN-gamma deficiency underlies mycobacterial disease. J VSports注册入口. Clin. Invest. 130: 3158-3171, 2020. [PubMed: 32163377, related citations] [Full Text] .


Creation Date:
Cassandra L. Kniffin : 07/28/2020
joanna : 08/19/2020
alopez : 07/31/2020
ckniffin : 07/28/2020

# 618963

IMMUNODEFICIENCY 69; IMD69


Alternative titles; symbols

IMMUNODEFICIENCY 69, MYCOBACTERIOSIS, AUTOSOMAL RECESSIVE
IFNG DEFICIENCY, AUTOSOMAL RECESSIVE


ORPHA: 699618;   DO: 0112006;   MONDO: 0033541;  


Phenotype-Gene Relationships

Location Phenotype Phenotype
MIM number
Inheritance Phenotype
mapping key
Gene/Locus Gene/Locus
MIM number
12q15 ?Immunodeficiency 69, mycobacteriosis 618963 Autosomal recessive 3 IFNG 147570

TEXT

A number sign (#) is used with this entry because of evidence that immunodeficiency-69 (IMD69) is caused by homozygous mutation in the IFNG gene (147570) on chromosome 12q15. One such family has been reported V体育2025版.


Description

Immunodeficiency-69 (IMD69) is an autosomal recessive disorder characterized by increased susceptibility to disseminated mycobacterial infection, including after BCG (bacille Calmette-Guerin) vaccination. Affected individuals develop fever, hepatosplenomegaly, leukocytosis, and thrombocytosis during the acute infection. There appears to be normal immunologic function against other pathogens, including viruses and bacteria VSports. Immunologic work-up shows normal parameters, but patient T and NK cells fail to produce gamma-interferon (IFNG) when stimulated in vitro (summary by Kerner et al. , 2020). .

IMD69 is a form of mendelian susceptibility to mycobacterial disease (MSMD) (see, e VSports app下载. g. , IMD27A; 209950).


Clinical Features

Kerner et al. (2020) reported 2 children from a large consanguineous kindred of Lebanese descent who developed disseminated mycobacterial disease following BCG vaccination in early infancy. Clinical features included prolonged fever and hepatosplenomegaly; 1 patient developed a maculopapular rash. Laboratory studies showed leukocytosis, anemia, thrombocytosis, and elevated liver enzymes. One patient was treated with recombinant gamma-interferon. However, she later developed features of hemophagocytic lymphohistiocytosis (HLH) with fever, splenomegaly, pancytopenia, high ferritin (see 134790), and increased triglycerides. Mutations in known HLH genes were excluded, and no infectious agent was identified. She underwent hematopoietic bone marrow transplant at 3 years of age, but died soon thereafter. The second patient, who was a first cousin of the first patient, had a similar early disease course after BCG vaccination and was successfully treated with antimycobacterial medications. Other immunologic parameters in the patients were normal, and antibody testing indicated that both patients had been exposed to bacteria and viruses, including respiratory syncytial virus (RSV), herpes, and opportunistic bacteria, but neither developed significant disease with these organisms.


Inheritance

The transmission pattern of IMD69 in the family reported by Kerner et al. (2020) was consistent with autosomal recessive inheritance.


Molecular Genetics

In 2 patients from a large consanguineous kindred of Lebanese descent with IMD69, Kerner et al. (2020) identified a homozygous frameshift mutation in the IFNG gene (147570.0005). The mutation, which was found by a combination of homozygosity mapping and whole-exome sequencing and confirmed by Sanger sequencing, segregated with the disorder in the family. Patient cells showed decreased levels of IFNG mRNA compared to controls, suggesting some mRNA decay of the mutant transcript. The predicted truncated protein, if expressed, would lack the C-terminal domain and likely be nonfunctional. In vitro functional expression studies of patient T cells and cells transfected with the mutation showed impaired IFNG production when stimulated and impaired induction of HLA-DR compared to controls, consistent with a complete loss of IFNG function. These cellular defects could be partially rescued by expression of wildtype IFNG.


REFERENCES

  1. Kerner, G., Rosain, J., Guerin, A., Al-Khabaz, A., Oleaga-Quintas, C., Rapaport, F., Massaad, M. J., Ding, J.-Y., Khan, T., Ali, F. A., Rahman, M., Deswarte, C., and 18 others. Inherited human IFN-gamma deficiency underlies mycobacterial disease. J. Clin. Invest. 130: 3158-3171, 2020. [PubMed: 32163377] [Full Text: https://doi.org/10.1172/JCI135460]


Creation Date:
Cassandra L. Kniffin : 07/28/2020

Edit History:
joanna : 08/19/2020
alopez : 07/31/2020
ckniffin : 07/28/2020